Page 8 - United Biosource News Today : Breaking News, Live Updates & Top Stories | Vimarsana

05.12.21 -- Partners Ready To Support Your Post-Approval Studies     As an established leader with decades of experience in Real-World Evidence (RWE) generation – UBC offers clients a distinct advantage as they move their specialty product from clinical development to the market.     When patients are waiting for life-altering treatments, every milestone is critical, Precision applies demonstrated expertise from quantifying the burden of disease for narrow patients populations to demonstrating and communicating the economic and clinical value of cell and gene therapies, traversing the c...

05.12.21 -- How Is The Shift To Decentralized Trials Impacting Clinical Sites?   Sponsor Is clinical development prepared for the paradigm shift caused by COVID-19? The pandemic has forced the industry to reevaluate how to engage with patients and acquire patient data without direct, in-person access. Biopharmaceutical companies, medical device companies, and CROs from around the world were surveyed to explore the impact on clinical trials in this new paradigm and gain insights into their experiences operationalizing trials in a pandemic. Learn more. Feature...

05.05.21 -- Partners Ready To Support Your Phase I-III Trials     Cytel brings its expertise in adaptive designs to the design and implementation of the industry’s most innovative clinical trials. These highly flexible trials raise peculiar challenges for enrollment, data collection and regulatory submission. Why not have the industry leaders in adaptive design working on your adaptive trials?     Are you preparing to initiate your clinical trial? Trying to get your next milestone quickly? Determining whether to outsource? We can help you answer the questions that keep you up at night. ...

Posted Mar 09, 2021 UBC, a comprehensive late stage research and patient-support services organization, is announcing an offering to harness the power of real-world data (RWD) for rapid generation of insights into the safety and effectiveness of COVID-19 vaccines.     As vaccine manufacturers prepare for post authorization surveillance initiatives to generate outcome evidence in real-world settings, the ability to rapidly automate analysis of large-scale representative databases is essential.  UBC’s Executive Director, Real World Evidence, Aaron Berger comments on the dynami...

Adverse Event Reporting Software Segment to Grow at Highest CAGR During 2020-2027 Pharmacovigilance and Drug Safety Software Market is expected to reach US$ 292.97 Mn in 2027 from US$ 160.67 Mn in 2019. The market is estimated to grow at a CAGR of 7.6% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth. Factors such as rising incidences of adverse drug reaction (ADR) and globalization of pharmacovigilance have been boosting the market over the years. However, the expensive technology is likely to have a negative...